RME Hot Seat: Prognosis, Treatment Choice, and Risk Management for CLL and MCL
Jointly provided by
This activity is supported by educational grants from AbbVie; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Release date: 4/20/2020
Expiration date: 4/21/2021
Estimated time to complete: 0.5 hour
Overview
With the emergence of new targeted therapies and new prognostic indicators and goals of treatment, the clinical management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)—for patients in the frontline and relapsed/refractory settings—has evolved significantly.
In this Q&A-based activity, our experts provide practical, evidence-based answers to questions relating to several of the most consequential changes in CLL/MCL patient care, including diagnostic and prognostic risk indicators, novel agents for the frontline and relapsed/refractory setting, and managing adverse events and intolerance.
Faculty
Anthony Mato, MD, MSCE—Program Chair
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York
John M. Pagel, MD, PhD
Chief of Hematologic Malignancies
Director of Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington
Chaitra S. Ujjani, MD
Clinical Associate Professor of Medicine
Division of Medical Oncology
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center
Seattle, Washington
Independent Peer Reviewer
Amit K. Verma, MBBS
Professor, Department of Medicine (Oncology)
Professor, Department of Developmental & Molecular Biology
Albert Einstein College of Medicine
Director, Division of Hemato-Oncology, Montefiore Department of Oncology
Montefiore Medical Center
Bronx, New York
CE Reviewer
Victor B. Hatcher, PhD
Associate Dean, Continuing Professional Development
Albert Einstein College of Medicine
Director, Center for Continuing Professional Development
Montefiore Medical Center
Bronx, New York
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care professionals involved in the care of patients with CLL or MCL.
Learning Objectives
At the conclusion of this activity, participants will be better able to:
- Interpret cytogenetic, molecular, and other standard staging tests to define risk and prognosis
- Distinguish the indicated uses, mechanisms of action, depth and duration of clinical responses, and safety of current and emerging targeted agents
- Evaluate recent data on treatment advances and strategies for managing CLL and MCL and their potential implications for clinical practice
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure
The “Policy on Collection of Relevant Financial Relationships and Resolution of COI” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CE activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company.* Any presenter whose disclosed relationships create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
*The ACCME defines a commercial interest as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interest—unless the provider of the clinical service is owned, or controlled by, an ACCME-defined commercial interest.
Faculty
Anthony Mato, MD, MSCE, has disclosed the following relevant financial relationships:
Consultant: AbbVie, BioPharma, Celgene Corporation, Johnson & Johnson, Pharmacyclics, Sunesis Pharmaceuticals, TG Therapeutics
Principal Investigator: AbbVie, Acerta Pharma, AstraZeneca, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics
John M. Pagel, MD, PhD, has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, Gilead, Pharmacyclics
Principal Investigator: AstraZeneca, Gilead, Pharmacyclics
Chaitra Ujjani, MD, has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, Atara Biotherapeutics, Genentech, Gilead, Rigel Pharmaceuticals
Principal Investigator: AbbVie, AstraZeneca, Gilead, Pharmacyclics
Reviewers
Victor B. Hatcher, PhD, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Amit K. Verma, MBBS, has no relevant conflicts of interest with any ACCME-defined commercial interest.
RedMedEd
Yvette Murley, PhD, Director of Scientific Services, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Heather Rafa, Project Manager, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Jonathan S. Simmons, ELS, Senior Managing Editor, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Karen Smith, Creative Director, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Unapproved Product Use
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Idelalisib is not indicated as frontline therapy for the treatment of CLL and is under investigation for the treatment of MCL. Umbralisib, CAR-T therapy, LOXO-305, ArQule 531, and vecabrutinib are under investigation for the treatment of CLL and/or MCL and not approved for use. Albert Einstein College of Medicine-Montefiore Medical Center; RedMedEd; AbbVie; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, do not recommend the use of any agent outside the labeled indications.
Disclaimer
The information presented in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center; RedMedEd; AbbVie; Pharmacyclics LLC, an AbbVie Company; or Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the posttest (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately.
Contact Information
For questions regarding CE credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at 718.920.6674 or cme@montefiore.org.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.
Hardware/Software Requirements
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome or Firefox 66.0.2 or higher
- Internet browser (Mac): Google Chrome, Firefox 66.0.2, or Safari 10.14 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
Privacy
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development protects the privacy of personal and other information regarding participants and educational collaborators. We will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting to the ACCME.
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
Additional information regarding Albert Einstein College of Medicine-Montefiore Medical Center's Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx.
Copyright
© 2020. This CE-certified activity is held as copyrighted by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd. Through this notice, Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.